STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $565,880.68 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68. Following the completion of the transaction, the insider now owns 11,289,437 shares of the company’s stock, valued at $174,873,379.13. This represents a 0.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were purchased at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The shares were purchased at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The stock was bought at an average price of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Price Performance

Shares of STAA opened at $15.35 on Friday. The company has a market capitalization of $756.45 million, a price-to-earnings ratio of 34.89 and a beta of 0.62. The business’s 50-day moving average is $23.37 and its 200-day moving average is $28.89. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68.

Institutional Investors Weigh In On STAAR Surgical

A number of large investors have recently added to or reduced their stakes in STAA. Resona Asset Management Co. Ltd. bought a new stake in STAAR Surgical during the fourth quarter worth approximately $36,411,000. Vanguard Group Inc. boosted its position in STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares during the period. Yunqi Capital Ltd boosted its position in STAAR Surgical by 48.9% during the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after purchasing an additional 252,113 shares during the period. JPMorgan Chase & Co. boosted its position in STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of STAAR Surgical by 25.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock worth $20,728,000 after buying an additional 171,046 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

STAA has been the subject of a number of research analyst reports. Piper Sandler dropped their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday. William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday. Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, STAAR Surgical has a consensus rating of “Hold” and an average price target of $26.86.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.